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Background: A close association between HIV infection and the development of cancer exists. Although the
advent of highly active antiretroviral therapy has changed the epidemiology of AIDS-associated malignancies, a
better understanding on how HIV can induce malignant transformation will help the development of novel
therapeutic agents.
Methods: HIV has been reported to induce the expression of DNMT1 in vitro, but still no information is available
about the mechanisms regulating DNMT expression in HIV-related B-cell lymphomas.
In this paper, we investigated the expression of DNMT family members (DNMT1, DNMT3a/b) in primary cases of
aggressive B-cell lymphomas of HIV-positive subjects.
Results: Our results confirmed the activation of DNMT1 by HIV in vivo, and reported for the first time a marked
up-regulation of DNMT3a and DNMT3b in HIV-positive aggressive B-cell lymphomas. DNMT up-regulation in
HIV-positive tumors correlated with down-regulation of specific microRNAs, as the miR29 family, the miR148-152
cluster, known to regulate their expression. Literature reports the activation of DNMTs by the human polyomavirus
BKV large T-antigen and adenovirus E1a, through the pRb/E2F pathway. We have previously demonstrated that the
HIV Tat protein is able to bind to the pocket proteins and to inactivate their oncosuppressive properties, resulting in
uncontrolled cell proliferation. Therefore, we focused on the role of Tat, due to its capability to be released from
infected cells and to dysregulate uninfected ones, using an in vitro model in which Tat was ectopically expressed
in B-cells.
Conclusions: Our findings demonstrated that the ectopic expression of Tat was per se sufficient to determine
DNMT up-regulation, based on microRNA down-regulation, and that this results in aberrant hypermethylation of
target genes and microRNAs.
These results point at a direct role for Tat in participating in uninfected B-cell lymphomagenesis, through dysregulation
of the epigenetical control of gene expression.
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A close association between Human Immunodeficiency
Virus (HIV) infection and the development of a number
of cancers, NHL being the second most common, has
been described. Interestingly, AIDS-associated lymph-
omas are of B-lymphoid origin in at least 95% of all cases
described despite the fact that HIV infects T-lymphocytes
[1], raising the question whether HIV may have a direct
role in B-cell lymphomagenesis. To date, there are no
clear answers to explain how HIV leads to transformation,
even though several events have been proposed as co-
factors in HIV-related tumorigenesis. The frequencies of
different subpopulations of B-cells have been reported
altered in the presence of HIV Reviewed in [2]. These
changes include increased frequency of activated and
terminally differentiated B-cells expressing low levels of
CD21 that have been associated with ongoing viral repli-
cation [3,4], a decreased frequency of memory B-cells that
is not reversed by antiretroviral therapy [5], and an in-
creased frequency of immature/transitional B-cells that
has been associated with CD4+ T-cell lymphopenia [6-8].
Although there is no indication of a direct role for the
virus in the B-cell transformation, lymphadenopathy, poly-
clonal B-cell proliferation, and even lymphoma may pre-
cede overt compromise of T-cell immunity [9,10]. In
addition, changes in the microenvironment of the host
cells have been recorded following HIV infection [11], as
well as chronic immune activation and dysfunctional cyto-
kine production that have been described throughout all
stages of HIV-1 infection [12].
In addition to these indirect effects, HIV may directly
contribute to B-cell transformation through its encoded
proteins and/or viral microRNAs (miRNAs), using which
it can disturb gene and miRNA expression in host cells
[13]. It is noteworthy that most transformed B-cells do
not contain the virus, therefore some other mechanisms
and/or viral factors may contribute to transformation. In
particular, several findings support an oncogenic role of
the HIV-1 Tat protein, which is essential for viral gene
expression and virus production [14-16]. A soluble, bio-
logically active form of Tat is released by HIV-infected
cells, taken up and translocated to the nucleus by neigh-
bouring uninfected ones [17-19], and may directly con-
tribute to B-cell abnormalities in HIV-positive patients
[20]. We have previously demonstrated that B-cell lymph-
omas of HIV-infected individuals may be positively stained
by an anti-Tat antibody [21]. Therefore it is reasonable to
hypothesize that the endocytosed Tat, released from in-
fected cells, may then exert its pleiotropic activities in un-
infected B-cells. Tat has been reported to modulate the
expression of several cellular genes, including cytokines
and their receptors [22-24]. In particular, the ability of Tat
to increase the expression of interleukins-6 (IL-6) and 10
(IL-10) [25,26], which in turn promote B-cell stimulation,and the evidence that about 30% of Tat-transgenic mice
develop B-cell lymphomas [27], suggest that Tat might play
a role in the pathogenesis of HIV-related B-lymphomas. In
particular, IL-6 has been reported to induce the over-
expression of the DNA Methyltransferase 1 (DNMT1),
which has a key role in the maintenance of DNA methyla-
tion, and epigenetically regulate the expression of several
genes, in liver cancer through miRNA dysregulation, which
correlates with increased genomic methylation [28]. Inter-
estingly, HIV has been reported to induce the expression
of DNMT1 [29,30] in vitro, though there is no evidence
that this can be exerted through IL-6 in HIV-positive indi-
viduals, although serum IL-6 is significantly elevated in
HIV+ subjects who develop aggressive B-cell lymphomas
[31]. In addition, induction of DNMT aberrant activity has
been reported by several human viruses through the pRb/
E2F pathway [32]. In particular, this occurs through the
interaction of viral products with the RB proteins and their
consequent inactivation [33-37]. Noteworthy, we have pre-
viously reported the physical interaction of Tat with the
pocket proteins, which results in their inactivation and in-
hibition of their growth regulatory properties [21,38]. This
suggests that Tat may contribute to DNMT aberrant ex-
pression in HIV-positive subjects.
In this paper we have investigated the possible mecha-
nisms used by HIV to induce DNMT over-expression. In
particular, we have analyzed whether DNMT induction by
HIV could depend on specific miRNA dysregulation, as
reported in liver cancer [28,39]. Our results show that
DNMT1, DNMT3a/b are up-regulated in B-cell lymph-
omas, and that this relies on down-regulation of specific
miRNAs. To assess the possible contribution of Tat,
we used an in vitro model, in which Tat was ectopically
expressed in uninfected B-cells. The ectopic expression of
Tat resulted in the up-regulation of DNMT1, DNMT3a/b
based on down-regulation of specific miRNAs, in accor-
dance to what we observed in HIV-positive primary
tumors.
DNMT over-expression may result in altered methyla-
tion pattern of genes and/or microRNAs, therefore we
investigated whether it may affect the expression of genes
frequently reported to be inactivated by hypermethylation,
as INK4/p16,TP53 and RB1. In addition, we tested whether
down-regulation of DNMT-regulating miRNAs detected in
our cell model was possibly dependent on hypermethyla-
tion as well, in a feedback-loop mechanism fashion. Here
we show that the ectopic expression of Tat determines an
altered methylation pattern of INK4/p16 and of specific
miRNAs, this finding being also confirmed in HIV-positive
tumors.
These results point out at the possible role for Tat in par-
ticipating in B-cell lymphomagenesis in uninfected cells,
through dysregulation of the host cell miRNA machin-
ery and of the epigenetic control of gene expression,
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chanisms of B-cell lymphomagenesis in HIV-infected
individuals.Methods
Ethics statement
The Institutional Review Board of the University of
Siena (Italy) and the Ethics and Research Committee of
the University of Nairobi (Kenya) gave ethics approval
for this study. Informed written consent was obtained in
all cases.Case selection and immunophenotype
For this study aggressive 30 formalin-fixed paraffin-
embedded (FFPE) cases of HIV-positive B-cell lymphoma
(DLBCL, BL) and 30 formalin-fixed paraffin-embedded
cases of HIV-negative B-cell lymphoma (DLBCL, BL) col-
lected at the Department of Pathology, Nairobi Hospital,
Kenya and the Department of Human Pathology and On-
cology, University of Siena, Italy, have been used. Cases
were reviewed by expert pathologists (BC, LL) and diag-
noses were confirmed by morphology on histological
slides stained with HE, Giemsa and by immunophenotyp-
ing, according to the Word Health Organization (WHO)
[1]. 5 reactive lymph nodes were used as negative controls.
Immunohistochemical studies were performed on repre-
sentative paraffin sections from each case using micro-
wave pre-treatment of slides for antigen retrieval, as
previously reported [40]. A large panel of antibodies recog-
nizing formalin-resistant epitopes of the various antigens
was applied (Table 1). The presence of the Epstein-Barr
virus (EBV) was assessed by in situ hybridization for EBERs
as described [41]. HIV-positive cases were mostly positive
for EBV.Table 1 List of the antibodies used for
immunohistochemistry












CD38 1:100 DakoPCR for detection of HIV infection
All of the HIV-positive lymphomas were tested for HIV
genome presence. A fragment of the HIV-1 DNA was
amplified by nested PCR using the lentivirus universal pri-
mer pair UNIPOL1/2 as outer primers (25 cycles) and the
degenerate primers UNIPOL3 (50-GAAACAGGAMRRG
AGACAGC-30) and UNIPOL4 (50-TTCATDGMTTCC
ACTACTCCTTG-30) as inner primers (30 cycles) [42].
This nested primer set, when used at low-stringency an-
nealing, specifically amplifies all HIV-1 and HIV-2 pol se-
quences known to date. PCR products were visualized on
agarose gels and the specificity of the products was con-
firmed by direct sequencing.Computational analysis
miRNAs predicted to regulate the expression of DNMT1
(hsa-miR-130a, hsa-miR-130b, hsa-miR-148a, hsa-miR-
148b, hsa-miR-152, hsa-miR-301) and DNMT3a/b (hsa-
miR-29a, hsa-miR-29b and hsa-miR-29c, hsa-miR-148a,
hsa-miR-148b) were identified by computational analysis,
using web-available resources (Mirnaviewer, PicTar, Tar-
base [43] and miRBase [44]; mirnaviewer is available at
http://cbio.mskcc.org/mirnaviewer; PicTar is a project of
the Rajewsky lab at NYU's Center for Comparative Func-
tional Genomics and the Max Delbruck Centrum, Berlin).
Among the many available by bioinformatics predictions,
these specific miRNAs were selected for this study as
regulation of DNMTs by these miRNAs through direct
mRNA binding has been previously proved [45,46].MiRNA extraction
Extraction of miRNAs from FFPE sections of primary tu-
mors and reactive lymph nodes was performed using the
miRNA easy FFPE kit (Qiagen, Carlsbad, CA), following
manufacturer’s instructions. Quality and purity of RNA
were assessed by spectrophotometric read using Nano-
drop (Thermo Scientific, Wilmington, DE) and by Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA).Analysis of miRNA expression
MiRNA expression was analyzed by RT-qPCR as previ-
ously described [41]. For each sample, 10 ng of total RNA
were reverse transcribed. Real-time PCR was performed
using Taqman probes specific for each miRNA (hsa-miR-
130a, hsa-miR-130b, hsa-miR-148a, hsa-miR-148b, hsa-
miR-152, hsa-miR-301, hsa-miR-29a, hsa-miR-29b and
hsa-miR-29c), and for RNU43, used as an endogenous
control (Applied Biosystems, Applera, Italy). Amount and
quality of RNA were evaluated measuring the OD at
260 nm, the 260/230 and the 260/280 ratios by Nanodrop
(Celbio, Italy).
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Relative quantification of gene expression for Cyclin A,
DNMT1, DNMT3a, DNMT3b, INK4/p16, RB1 and TP53
was also carried out by Real-time PCR using FluoCycle
SYBR green (Euroclone, Celbio, Italy) according to man-
ufacturer’s instructions. HPRT was used as housekeeping
gene. The complete list of primers used for qPCR is pro-
vided in Table 2. Differences in gene expression were
calculated using the ΔΔCt method [47].
Recombinant Tat
The recombinant Tat HIV-1 IIIB (aa 1–86) from Dr J
Raina was obtained through the EU Programme EVA/
MRC Centralised Facility for AIDS Reagents, NIBSC, UK
(Grant numbers QLK2-CT-1999-00609 and GP828102).
The stock solution was diluted in saline citrate buffer as
recommended, and aliquots were stored at −80°C until
use. The concentration of endotoxin was below 0.01 endo-
toxin unit (EU)/mg of protein. Extracellular Tat (50 ng/ml)
was added to the medium culture of cells for 48 h. Cells
grown in the absence of Tat were used as a control.
Ectopic expression of Tat in vitro
Tat ectopic expression was either obtained through ex-
posure to recombinant Tat or through transient and stable
transfections, by nucleofection. A Burkitt lymphoma-
derived EBV-negative cell line (Ramos) was used to per-
form the in vitro experiments. Briefly, cells were cultured
in RPMI supplemented with 10% FBS, 1% L-glutamine,
penicillin/streptomycin, with 5% CO2, at 37°C. The re-
combinant Tat was used as previously described [38]. CellsTable 2 Primers used for qPCR
Gene Primer sequence
CYCLIN A-FORWARD 5’-AGG CTT CAA AGT ACC TGT GTG-3’
CYCLIN A-REVERSE 5’-TTG ATC CCA CGT GCA GAA G-3’
DNMT1-FORWARD 5’-CGACTACATCAAAGGCAGCAACCTG-3’
DNMT1-REVERSE 5’-TGGAGTGGACTTGTGGGTGTTCTC-3’
DNMT3A-FORWARD 5’-TAT TGA TGA GCG CAC AAG AGA GC-3'
DNMT3A-REVERSE 5’-GGG TGT TCC AGG GTA ACA TTG AG-3'
DNMT3b-FORWARD 5’-GGC AAG TTC TCC GAG GTC TCTG-3'
DNMT3b-REVERSE 5’-TGG TAC ATG GCT TTT CGA TAG GA-3'
RB1 FORWARD 5’-CAC CAA TAC CTC ACA TTC CTC-3'
RB1 REVERSE 5’-TTC TCA GAA GTC CCG AAT G-3’
TP53 FORWARD 5’-CCA TCC TCA CCA TCA TCA C-3'
TP53 REVERSE 5’-GGC AGT GCT CGC TTA GTG G-3'
INK4/p16 FORWARD 5'-GGA AGG TCC CTC AGA CAT C-3'
INK4/p16 REVERSE 5’-GCA GTT GTG GCC CTG TAG-3'
Primers for CYCLIN A amplified a region of 105 bp; Primers for DNMT1
amplified a region of 88 bp; Primers for DNMT3a amplified a region of 68 bp;
Primers for DNMT3b amplified a region of 68 bp; Primers for RB1 amplified a
region of 152 bp; Primers for TP53 amplified a region of 140 bp; Primers for
INK4/p16 amplified a region of 67 bp.grown in the absence of Tat were used as a negative con-
trol. Transient and stable transfections were performed by
nucleofection, using an Amaxa apparatus, program T16
and solution T (Amaxa, Cologne, Germany). A transfec-
tion efficiency of 45% was obtained, as assessed by FACS
analysis for a GFP reporter. Cells (2x106) were transfected
with 10 μg of pCDNA3-Tat [38], using the empty vector
as negative control. In addition, a stable Tat-transfected
Ramos cell line was obtained by antibiotic selection with
G-418, at the concentration of 2 mg/ml.
Cell proliferation
The effect of Tat on cell proliferation was assessed as
previously described [40]. Briefly, cell counts were estab-
lished by Tripan blue staining and the possible effect of
Tat on the cell cycle was monitored by analysis of Cyclin
A expression, used as a specific S-phase marker, by RT-
qPCR, as described above. In addition, proliferation was
also monitored following transfections with miRNA
mimics and inhibitors (see below). Statistical significance
was assessed by the analysis of variance (ANOVA) test.
miRNA nucleofection
To assess the regulation of the target genes by the pre-
dicted miRNAs in our cell model, modulation of the en-
dogenous miRNAs was obtained by synthetic miRNAs
and inhibitors (Dharmacon, Celbio, Milan, Italy), through
nucleofection, followed by detection of the expression of
the genes of interest. Briefly, cells were split the day before
nucleofection and 5x106 cells were transfected with differ-
ent concentrations of either the miRNA mimic or inhibitor
(10 nM, 50 nM or 100 nM), to assess the best dose–
response concentration. Negative control of mimics and
inhibitors (NC, NCI, respectively) were used at the 10 nM
concentration (Dharmacon, Euroclone, Milan, Italy). As
the selected miRNAs regulating DNMT1 map in clusters,
we used one mimic/inhibitor for each cluster. In particular,
mimics and inhibitors of hsa-miR130a, hsa-miR152 and
hsa-miR29 were used to modulate the endogenous expres-
sion of DNMT1 and DNMT3a/b, respectively (all from
Dharmacon, Euroclone, Milan, Italy). To analyze the down-
stream DNMT modulation, mimics and inhibitors were
used at the concentration which gave the best effect. RNA
was extracted 24 hours after nucleofection and both gene
expression for DNMTs and miRNA expression were
checked by Real-Time RT-PCR, as previously described.
Western blotting
Cells pellets were lysed on ice for in EBC buffer (50 nM
Tris–HCl pH 8.0, 130 mM NaCl, 1% Triton X-100, 0.1%
SDS) supplemented with protease inhibitor cocktail
(Sigma, Milan-Italy). Cell lysates were separated by 10%
SDS-PAGE gel followed by transfer to Hybond ECL
nitrocellulose membrane (GE Healthcare, Milan, Italy).
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BD, NJ USA), anti-DNMT3a (1:250, Abcam, UK) and
anti-actin (1:1000, BD, NJ USA). Secondary antibodies
conjugated with HRP were used at a dilution of 1:5000
and the reaction was revealed using the ECL Western
Blotting Kit (Promega, Milan-Italy) according to the
manufacturer’s instructions.DNA extraction and methylation assay
FFPE section (10 μm) of 5 cases of DLBCL HIV-positive,
5 cases of DLBCL HIV-negative and 2 reactive lymph
nodes were deparaffinized with xylene and DNA extrac-
tion was performed with NucleoSpin kit (Macherey-
Nagel), according to manufacturer’s instructions. Amount
and quality of DNA were evaluated measuring the OD at
260 nm, the 260/230 and the 260/280 ratios by Nanodrop
(Celbio, Italy). DNA quality control PCR was also per-
formed as previously described (21). 500 ng of DNA
of each case were modified by bisulfite (EZ DNA
Methylation-Gold kit ZYMO RESEARCH) according
to manufacturer’s instructions. Approximately 100 ng
of converted DNA were amplified using methylation
specific primers (MSP) or bisulfite sequencing primers
(BSP). Primer sequences for MSP are provided in
Table 3. PCR products were separated on a 2% agarose
gel to confirm size. For methylation assay primers were
designed using the MethPrimer (MethPrimer - Li Lab,
UCSF www.urogene.org/methprimer/index1.html). For
some microRNAs the software did not identify any
CpG islands (hsa-miR130b, hsa-miR148b, hsa-miR301,
hsa-miR-29a, hsa-miR-29b, hsa-miR-29c), therefore
methylation was assessed for miRNAs containing CpG
islands. In some cases, designed primers amplified a
product size which was too long to be amplified in our
primary tumors, according to the DNA quality control,
and therefore they were discarded. Methylation wasTable 3 Primer sequences for MSP
Gene Primer sequence
INK4/p16 U FORWARD 5’-TTA TTA GAG GGT GGG GTG GAT TGT-3’
INK4/p16 U REVERSE 5’-CAA CCC CAA ACC ACA ACC ATA A-3’
INK4/p16 M FORWARD 5’-TTA TTA GAG GGT GGG GCG GAT CGC-3’
INK4/p16 M REVERSE 5’-GAC CCC GAA CCG CGA CCG TAA-3’
TP53 U FORWARD 5’-TTT TTT AGG TAG TTT TTG GTT TTG T-3’
TP53 U REVERSE 5’-ACC AAA CCT CTC AAA TTA CAA CAA T-3’
TP53 M FORWARD 5’-ATT TTT TTA GGT AGT TTT CGG TTT C-3’
TP53 M REVERSE 5’-GAA CCT CTC AAA TTA CGA CGA T-3’
Primers for INK4/p16 unmethylated (U) amplified a region of 151 bp, primers
for INK4/p16 methyled (M) amplified a region of 150 bp; primers for TP53
unmethylated amplified a region of 134 bp, primers for TP53 methylated
amplified a region of 133 bp.therefore checked using different approaches, collect-
ively MSP and BSP, followed by direct sequencing, and
treatment with 5-Aza. Methylation assay was carried
out either in primary tumors or Tat-transfected cell
lines by MSP and BSP, according to the product size,
and by 5-Aza treatment in cell lines (see below). Pri-
mer sequences are reported in Table 4.Treatment with 5-aza-2-deoxycitidine
To test whether miRNA down-regulation in HIV-
positive tumors was possibly due to hypermethylation
following DNMT over-expression, Ramos cells (either
transfected or not with a vector coding for Tat) were
treated with 1 μM 5-aza-2-deoxycitidine as reported [41]
and relative quantification of miRNAs was made by RT-
qPCR two days after treatment, as previously described.Results
HIV induces the aberrant expression of DNMTs
HIV is reported to induce the expression of DNMT1
in vitro [29,30], though no information is available about
its effect on DNMT3a/b, and about their expression in
HIV-positive B-cell lymphomas. Therefore relative ex-
pression of DNMTs was checked in HIV-positive and HIV-
negative primary tumors of aggressive B-cell lymphomas vs.
reactive lymph nodes, both by RT-qPCR (Figure 1a)
and immunohistochemistry (Figure 1b-e), respectively.
DNMT1, DNMT3a/b were found up-regulated in HIV-
positive tumors (Figure 1a-e).
As DNMT dysregulation in cancer has been linked to
dysregulation of miRNAs [28,39,45,48,49], the expres-
sion of miRNAs known to directly regulate DNMTs was
investigated. Six miRNAs (hsa-miR-130a, hsa-miR-130b,
hsa-miR-148a, hsa-miR-148b, hsa-miR-152, hsa-miR-
301) have been reported to regulate the expression of
DNMT1 [28], whereas the miR29 family and also hsa-Table 4 Primer sequences for microRNA methylation
analysis
microRNA Primer sequence
hsa-miR148a FORWARD (BSP) 5’-TGGGTATTTGTTTTTGTTGATTG-3’
hsa-miR148a REVERSE (BSP) 5’ACTACACTTAAACCCCCTCTAACC-3’
hsa-miR152 FORWARD (BSP) 5’-GGAATTTTGTGTTATTTTTGATTG-3’
hsa-miR152 REVERSE (BSP) 5’CCAAACAAATATTCCACTACAAAC-3’
hsa-miR148a U-FORWARD (MSP) 5’TTGATGTTGTTAGTGTTTTAGATGT-3’
hsa-miR148a U-REVERSE (MSP) 5’AAAAAAATTAATCAAATTCCTCATA-3’
hsa-miR148a M-FORWARD (MSP) 5’GTCGATGTCGTTAGTGTTTTAGAC-3’
hsa-miR148a M-REVERSE (MSP) 5’AAAAAAATTAATCAAATTCCTCGTA-3’
hsa-miR148a hsa-miR148a (BSP) amplify a region of 326 bp; hsa-miR152 (BSP)
amplify a region of 435 bp. Appropriate primers for MSP were found by the
software only for hsa-miR148a, which amplify a region of 110 bp.
Figure 1 Expression of DNMTs in HIV+ vs. HIV- tumors. (a) Relative expression of DNMT1, DNMT3a/b in HIV+ vs. HIV− tumors by RT-qPCR.
Up-regulation of all these genes is observed in HIV+ samples (p < 0.05). (b-c) IHC using an anti-DNMT1 antibody in HIV-negative cases (b) and
HIV-positive cases (c). (d-e) IHC for DNMT3a in HIV-negative (d) and positive (e) cases. Up-regulation of DNMT1 and DNMT3a was detected in
HIV-positive tumors. None of the antibodies tested for DNMT3b was useful for IHC.
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Figure 2 miRNAs predicted to regulate DNMT1, DNMT3a/b were analyzed by RT-qPCR in HIV+ vs. HIV− primary tumors. A strong and
significant down-regulation of all the selected miRNAs regulating DNMTs is observed in HIV-positive tumors (p < 0.05). The graph is representative
of three different RT-qPCR experiments. Error bars represent standard deviation between duplicates.
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a marked down-regulation of all the selected DNMT-
regulating miRNAs in HIV-positive tumors (Figure 2), in
respect with HIV-negative samples and normal lymph
nodes.Figure 3 Immunoistochemical staining for p24 and Tat in HIV+ vs. HIV
of macrophages in a B-cell lymphoma of a HIV-positive subject. (b-c) IHC
(c). Marked positivity to Tat of uninfected B-cells is visible in HIV-positive t
from infected cells and enters neighbouring uninfected ones.DNMT expression is increased in Tat-transfected cells
We tested tumor tissues for the presence of HIV, which
was confirmed in our series of cases by p24 staining by
IHC (Figure 3a). Notably, HIV genome was not detected
in tumor B-cells (data not shown), though they showed- tumors. (a) IHC using an anti-p24 antibody showed marked positivity
using an anti-Tat antibody in HIV-negative (b) and HIV-positive cases
umors, thus indicating that a soluble form of the protein is released
Figure 4 DNMT expression in Tat-positive vs. Tat-negative cells. (a) Relative expression of Tat 24 h after transfection with a Tat-coding vector.
(b-c) Ectopic expression of Tat was obtained either upon exposure to the recombinant protein or following transfection of a Tat-coding vector. DNMT1,
DNMT3a/b expression was then analysed in Tat-positive (transfected or treated with soluble Tat) vs. Tat-negative cells (empty vector-transfected or
untreated cells) at the mRNA level by RT-qPCR (b); up-regulation of all DNMTs is obtained following Tat ectopic expression, both upon exposure to
recombinant Tat and following Tat-transfection (p < 0.05). (c) Western blotting analysis for DNMT1 and DNMT3a in Tat-positive vs. Tat-negative cells.
Up-regulation of both DNMTs is observed in Tat-positive cells, thus confirming results obtained in HIV-positive primary tumors. None of the tested
antibodies for DNMT3b was suitable for WB analysis. Quantification by densitometric analysis is reported.
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Figure 5 Expression of DNMTs and DNMT-regulating miRNAs in Tat-positive vs. Tat-negative cells. DNMT1 and DNMT3a/b-regulating
microRNA expression was checked by RT-qPCR in Tat-positive vs. Tat-negative cells following transient transfections and exposure to recombinant
protein (a). Down-regulation of all miRNAs is observed in Tat-positive cells. The graph is representative of three different RT-qPCR experiments.
Error bars represent standard deviation between duplicates. (b-d) Modulation of DNMT-regulating miRNAs was achieved by transient transfections
of either mimics or antagomirs of the endogenous miRNAs at different concentration, and the effect on the expression of their respective miRNAs
was monitored by RT-qPCR. DNMT1-regulating miRNAs (hsa-miR130a and hsa-miR152) are reported in (b-c), whereas DNMT3a/b regulating
miRNAs (hsa-miR29) are shown in (d). (e-f) Relative expression of DNMT1 (e), DNMT3a/b (f) was then evaluated following the ectopic modulation
of these miRNAs. Up-regulation of the specific miRNAs results in the down-regulation of DNMTs, whereas increased expression of DNMTs is
observed following miRNA inhibition. The graph is representative of three different RT-qPCR experiments (p < 0.05). Error bars represent standard
deviation between duplicates. (g-h): WB for DNMT1 and DNMT3a of cells transfected with hsa-miR152 (for DNMT1) and hsa-miR29 (for DNMT3a)
mimics and inhibitors. NC: Mimic negative control; M: Either hsa-miR152 or hsa-miR29 mimic; NCI: Inhibitor negative control; I: Either hsa-miR152
or hsa-miR29 inhibitor. None of the tested antibodies for DNMT3b was suitable for WB analysis. Densitometric analysis results are reported.
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up-regulation in B-cells was possibly resulting from a
soluble Tat released from infected cells and taken up by
uninfected B-cells, we used an in vitro model of B-cell
lymphoma in which Tat was ectopically expressed either
by exposure to soluble Tat or by transient and stable
transfections. Relative expression of DNMT1, DNMT3a/
b was then analyzed in our in vitro model by RT-qPCR
and western blotting. Ectopic expression of Tat, either
obtained by exposure to recombinant Tat or nucleo-
fection, gave overlapping results, which showed that
DNMTs are up-regulated following Tat ectopic expres-
sion, both at the mRNA and protein levels, as observed
in primary tumors (Figure 4a-c).
DNMT-regulating miRNAs are dysregulated in
Tat-transfected cell lines
We then checked whether Tat-dependent up-regulation
of DNMTs relied on miRNA down-regulation, as in
HIV-positive primary tumors. Our results demonstrated
that the ectopic expression of the Tat protein is sufficient
per se to determine DNMT-controlling miRNA down-
regulation, both in transient (Figure 5a) and in stable
Tat-transfected cells (data not shown). In addition, we
used miRNA mimics and antagonists to modulate the
expression of the endogenous miRNAs predicted to
regulate DNMTs. Different concentrations for each
mimic/antagonists were used, to assess the best dose–re-
sponse effect (Figure 5b-d). The expression of DNMTs
in cells transfected either with mimics or inhibitors was
then checked, using mimics/inhibitors at the concentra-
tion proved to have the highest efficiency. Enhanced
miRNA concentration resulted in decrease of DNMT1,
DNMT3a/b whereas the inhibition of endogenous miR-
NAs resulted in their up-regulation, thus confirming
regulation of DNMTs by the selected miRNAs in our
cell model (Figure 5e-f ). Western blotting confirmed
modulation of DNMTs using mimics/inhibitors. In par-
ticular, ectopic over-expression of the selected miRNAs
resulted in the down-regulation of DNMTs, whereasinhibition of the miRNA led to the consequent protein
up-regulation (Figure 5g-h).
Over-expression of DNMTs determines an increase of
gene and microRNA methylation
We have previously reported the physical interaction of
Tat with the RB family of proteins, which results in the
inactivation of their growth regulatory proteins [21,38].
Therefore, we monitored cell growth in Tat-transfected
cells and observed an enhanced cell proliferation (Fig-
ure 6a), which may depend on Tat-mediated alteration
of the G1/S transition of the cell cycle, through the
physical interaction of Tat with the pocket proteins
[21,38,50]. Notably, the expression of cyclin A, which is
a specific S-phase marker, was higher in Tat-expressing
cells, which is consistent with the enhanced proliferation
rate in Tat-positive cells (Figure 6b). Subsequently, we
checked the expression of RB1, INK4/p16 and TP53,
crucial cell cycle regulators, in Tat-transfected cell lines.
Our results demonstrate that the ectopic expression of
Tat resulted in down-regulated expression of INK4/p16
and TP53, whereas no difference was instead observed
for RB1 (Figure 6c). These in vitro results were then
confirmed in HIV-positive primary tumors, by RT-qPCR
(Figure 6d).
To verify whether down-regulation of INK4/p16 and
TP53 was a consequence of promoter hypermethylation,
DNA extracted from Tat-transfected cells and primary
tumors was modified by bisulfite treatment, followed
by MSP and BSP analyses. INK4/p16 was found hyper-
methylated both in Tat-transfected cells as well as in
HIV-positive tumors, whereas no methylation was de-
tected for TP53 (Figure 7a-b), whose down-regulation
may possibly depend on genetic alterations. Decreased
protein levels for p16 were also detected by IHC in HIV-
positive primary tumors, in line with the INK4/p16 gene
hypermethylation (Figure 7c). Hypermethylation was
also checked for those miRNAs containing CpG islands.
In particular, BSP and MSP analyses identified partial
methylation for hsa-miR148a and hsa-miR152 (Figure 7d),
Figure 6 Analysis of cell cycle regulators in Tat-positive vs. Tat-negative cells. Cell proliferation in Tat-transfected vs. empty vector-transfected
cells (a). Tat-transfected cells show a higher proliferation rate, which is in line with the increased expression of cyclin A (b), an S-phase specific marker.
(c-d) Relative expression by RT-qPCR of INK4/p16, TP53 and RB1 in Tat-transfected cells (c) and in HIV-positive vs. HIV-negative primary tumors
(d). Down-regulation of INK4/p16 and TP53 is observed both in vitro and in vivo. The graph is representative of three different RT-qPCR experiments
(p < 0.05). Error bars represent standard deviation between duplicates.
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(Table 5), whereas it was not possible to design appropri-
ate primers for hsa-miR130a, due to the length of the
product.5-Aza treatment was then performed in Tat-transfected
cell lines, to further confirm that miRNA down-regulation
was dependent on hypermethylation. Following 5-Aza
treatment, miRNA expression level was checked by RT-
Figure 7 Methylation analysis of DNMT-dependent miRNAs and cell cycle regulatory genes in Tat-positive vs. Tat-negative cells and
primary tumors. Methylation analysis of INK4/p16 (a) and TP53 (b) in HIV-positive and -negative primary tumors. M indicates the product using
the methyled primers, U indicates the product using the unmethyled primers. Amplification of INK4/p16 resulted in a band lower than 200 bp,
whereas the specific product for TP53 was about 100 bp. The specific product for INK4/p16 was obtained only using unmethyled primers in
HIV-negative samples, whereas only methyled primers resulted in a INK4/p16 product in HIV-positive tumors, which is indicative of INK4/p16
methylation in HIV-positive tumors. No differences were observed for TP53 between HIV-negative and HIV-positive tumors, as the amplified
product was obtained only using unmethyled primers, indicating that no methylation is detectable for TP53 in neither of the two tumor types.
Arrows indicate the presence of specific products for both genes. (c) IHC for p16 in HIV-positive tumors; (d) Sequence analysis of hsa-miR-148a in
HIV-positive and HIV-negative primary tumors. Arrows indicate the methyled C that are not converted to U in HIV-positive tumors.
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http://www.infectagentscancer.com/content/9/1/41qPCR. Our results demonstrated re-expression of miR-
NAs containing CpG islands (Figure 8a-b), whereas no
change in the expression was instead observed for those
miRNAs which do not contain CpG islands, as expected
(Figure 8a-b). In addition, treatment with 5-Aza restored
the expression of INK4/p16 in Tat-transfected cells, thus
confirming silencing of the gene through hypermethylationin the presence of Tat (Figure 8c). To further confirm
that down-regulation of INK4/p16 in the presence of
Tat was due to miRNAs regulating DNMTs, we modu-
lated the expression of the endogenous DNMT-
regulating miRNAs using synthetic mimics and antago-
mirs, and consequently evaluated the expression level of
INK4/p16. Our results demonstrated that the expression
Table 5 Analysis of methylated CpG sites for hsa-miR-148a




Total CpG islands 4 4
Methylated CpG 4 0
Unmethylated CpG 0 4
Hsa-miR-152
Total CpG islands 30 30
Methylated CpG 25 11
Unmethylated CpG 5 19
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http://www.infectagentscancer.com/content/9/1/41level of INK4/p16 varied according to the modulation of
DNMT-regulating miRNAs. In particular, inhibition of the
endogenous miRNAs, which determines DNMT over-
expression, resulted in a decreased expression of INK4/
p16, which is consistent with DNMT-dependent hyperme-
thylation. Conversely, ectopic up-regulation of the en-
dogenous miRNAs using synthetic mimics led to the up-
regulation of INK4/p16, as a consequence of a reduced
DNMT expression (Figure 8d).
As DNMT-mediated silencing of INK4/p16 through
methylation may affect cell proliferation, due to the in-
activation of its growth arrest properties, we monitored
whether modulation of DNMT-regulating miRNAs
through mimics/inhibitors may eventually affect cell
growth. Our results show that inhibition of endogenous
DNMT-regulating miRNAs through antagomirs results in
an increased cell proliferation. Inhibition of endogenous
miRNAs may affect cell proliferation through the up-
regulation of DNMTs and consequent silencing of INK4/
p16, which results in the abolishment of cell growth arrest.
Conversely, DNMT down-regulation through miRNA
mimics determines an opposite effect on cell growth
(Figure 8e-f).
Discussion
Tumor viruses has been implicated in the etiology of
many cancers including malignant mesotheliomas, non-
Hodgkin's lymphoma and tumors of the bone, brain and
urinary tract [51-53]. The most commonly explored role
for viruses in cancer involves the expression of viral on-
cogenes, such as polyomavirus large T-antigens (TAg),
adenovirus E1a and E1b, and papillomavirus E6 and E7
[54]. These proteins share the ability to interact with
and inactivate the pocket protein family (pRb, p107,
p130) and/or the p53 tumor suppressor [55-58]. This re-
sults in the activation of the cellular DNA replication
machinery needed to replicate the viral genome and pro-
motes increased cellular proliferation, delayed differenti-
ation, and often malignant transformation [59].HIV infection is often associated with the onset of ma-
lignant lymphomas, 95% of which are of B-cell origin.
Some of them, as Burkitt lymphoma, may arise in im-
munocompetent patients, even before the AIDS mani-
festation. Due to the high CD4+ cell number of these
patients, it is reasonable to hypothesize that malignant
transformation in these cases may not be a consequence
of the immunodepression of infected individuals, sug-
gesting that HIV itself may be involved in driving the
transformation process. The virus encodes for many pro-
teins and viral microRNAs, using which it may compete
with cellular proteins/RNAs, thus disturbing the physio-
logical regulation of the host cell. As most transformed
B-cells do not contain the virus, some other mechanisms
and/or viral factors may be involved. Among these, the
most reliable candidate is the Tat protein, as it may func-
tion as a soluble effector, being released from infected
cells and taken up by uninfected B-cells, in a biologically
active form. Our previous studies demonstrated that
HIV-positive B-cell lymphomas may be positively stained
by an anti-Tat antibody [21] and again here we show
positivity for Tat in our set of B-cell tumors. Therefore
the endocytosed Tat may directly exert its biological
functions in uninfected B-cells.
The ability of Tat to act directly on B-cells and differ-
entially modulate the B-cell response of naïve/memory
and germinal center (GC) B-cells has been previously re-
ported [19]. Tat-mediated induction of GC B-cell prolif-
eration might therefore contribute to promote HIV-
associated follicular hyperplasia, autoimmune disorders
and B-cell malignancies. The effects of Tat are likely to
impact on the early stages of the cell cycle, before the
G1 to S phase transition, and on B-cell differentiation,
rather than affecting isotype switching [19]. In addition,
Tat has been shown to bind to the pocket proteins, thus
interfering with control of cell growth [21,38,50], which
may eventually result in transformation.
However, while genetic perturbations have been shown
to play key roles in viral transformation, epigenetic mod-
ifications such as DNA methylation may also play im-
portant roles during viral infection and transformation,
as viral infection affects de novo methylation and tran-
scription of cellular genes as well [60-62].
In this paper we have analyzed the expression of a par-
ticular class of proteins, the DNA Methyl Transferases,
which epigenetically regulate gene expression, as HIV-1
has been reported to induce the expression of DNMT1
in vitro, which has a key role in the maintenance of DNA
methylation, and epigenetically regulate the expression of
several genes [29]. Over-expression of DNMT1 correlates
with increased genomic methylation [30] and has been as-
sociated with miRNA dysregulation in liver cancer, in
which DNMT1 over-expression is induced by IL-6 over-
production [28]. Here, we show that HIV enhances the
Figure 8 (See legend on next page.)
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Figure 8 Modulation of DNMT-regulating miRNAs affects the expression of INK4/p16 and consequent cell growth control. Treatment
with 5-Aza in (a) empty vector-transfected and (b) Tat-transfected cells. Treatment with 5-Aza induces the expression of miRNAs containing CpG
islands in Tat-transfected cells, indicating that down-regulation of these miRNAs depends on hypermethylation. (c) Treatment with 5-Aza was
also able to restore the expression of INK4/p16 in Tat-transfected cells, thus suggesting that silencing of INK4/p16 is due to hypermethylation.
(d) Ectopic modulation of DNMT-regulating miRNAs was achieved using synthetic mimic or inhibitors. Relative expression of INK4/p16 was then
checked by RT-qPCR. A decreased expression of the gene was observed following inhibition of miRNAs, which leads to up-regulation of DNMTs
and consequent hypermethylation of target genes. Conversely, increased expression of endogenous miRNAs, which leads to downregulation of
DNMTs, results in over-expression of INK4/p16 (p < 0.05). NC: Mimic negative control; M: Either hsa-miR152 or hsa-miR29 mimic; NCI: Inhibitor
negative control; I: Either hsa-miR152 or hsa-miR29 inhibitor. (e-f) Cell proliferation analysis in cells transfected with miRNA mimics/inhibitors for
DNMT1 (e) and DNMT3a/b (f). Inhibition of the endogenous miRNAs enhances cell growth.
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http://www.infectagentscancer.com/content/9/1/41expression of DNMTs involved in both the basic and the
de novo methylation. Such up-regulation relies on the
down-regulation of specific miRNAs predicted to regulate
DNMTs, in primary tumors of aggressive B-cell lymph-
omas, compared to HIV-negative tumors and normal tis-
sues. The increased expression of DNMTs could result in
an altered pattern of methylation of target genes/miRNAs
in HIV-positive subjects. Noteworthy, reduction of the
global methylation has been recently reported in HIV-
positive subjects following HAART treatment [63], thus
supporting the finding that HIV is able to increase global
DNA methylation. As the HIV genome has not been de-
tected in the tumor tissues of the aggressive B-cell lymph-
omas we analyzed, we hypothesized that Tat, released in a
soluble form from infected cells, could contribute to ma-
lignant transformation of these cases. To test this hypo-
thesis, we used an in vitro model obtained by ectopic
expression of Tat in B-cells, either by cell transfections orFigure 9 A model for Tat-mediated lymphomagenesis. DNMT aberrant
Tat is able to induce both IL-6 expression and RBL2-gene product inactivat
these mechanisms, which results in the aberrant methylation of genes andexposure to recombinant Tat. In line with our in vivo re-
sults, we observed that the ectopic expression of Tat was
able to induce overexpression of DNMTs based on down-
regulation of DNMT-regulating miRNAs, pointing at a
direct role for Tat in regulating DNMT expression.
Based on the growth capability acquired by Tat-
transfected cells, which may depend on silencing of cell
cycle progression inhibitory genes, we have then ana-
lyzed whether key cell cycle regulatory genes, as INK4/
p16, TP53 and RB1, may be possibly silenced through
methylation, thus leading to the loss of the G1/S con-
trol [50], in Tat-transfected cells. Our results demon-
strate a down-regulated expression of INK4/p16 and
TP53, in Tat-transfected cells, whereas no difference is
observed for RB1. In addition, we show that the reduced
expression of INK4/p16, following ectopic expression of
Tat, was specifically due to hypermethylation, whereas no
methylation was detected for TP53. 5-aza-2-deoxycitidineactivity may be induced by both IL-6 and RB-protein inactivation. As
ion, we hypothesize that Tat may induce DNMT up-regulation through
miRNAs.
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NAs, for which CpG islands have been described, thus
suggesting that miRNA down-regulation Tat-transfected
cell lines may depend on hypermethylation resulting from
aberrant DNMT expression. The in vitro results were then
confirmed in HIV-positive primary tumors. Interestingly,
cell growth was affected by transfections of mimics/inhibi-
tors, as inhibition of the endogenous miRNAs resulted in
a higher proliferation rate. This may be due to the up-
regulation of DNMTs and consequent INK4/p16 silencing
through methylation, which removes the control on cell
growth and speeds up cell proliferation.
Transcriptional inactivation of DNMTs has been re-
cently reported to occur by Rb proteins and this effect
was shown to be reversible by Rb-inactivating viral onco-
proteins such as the T-antigen [32-36]. In particular, de-
creased DNMT expression has been linked to the activity
of the RBL2 gene product [37]. Notably, we have previ-
ously demonstrated that Tat is able to inactivate RBL2/
p130 through a physical binding [21,38]. This may repre-
sent an intriguing mechanism through which Tat up-
regulates DNMT expression in B-cells of infected patients
by inactivating RBL2 activity.
As Tat is also able to induce the expression of IL-6,
which in turn determines aberrant DNMT1 activity, we
may propose a model for Tat-mediated transformation
in B-cells of HIV-infected patients, who have high levels
of IL-6 (Figure 9). It is reasonable to hypothesize that a
soluble form of Tat, released from infected cells within
the B-cell tumor, is taken by uninfected B-cells. This bio-
logically active Tat is now able to modulate the expression
of several genes, including IL-6 [25]. The over-production
of IL-6, together with the Tat-mediated inactivation of
RBL2, could be then responsible for the up-regulated
expression of DNMTs, which determines an aberrant
methylation pattern of genes/microRNAs. Among these,
hypermethylation of INK4/p16 may be crucial, as its silen-
cing would lead to the loss of control on a key cell cycle
restriction point, as suggested by an enhanced cell prolif-
eration, which may then confer cells a growth advantage
and eventually result in malignant transformation.
Conclusions
The Tat-dependent modulation of DNA Methyl Trans-
ferases provides an attractive mechanism through which
it can restore and maintain methylation of critical genes
in HIV-infected individuals.
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